I’m part of the Leerink Partners equity research team. Marty Huber, CEO, Mersana: It’s a Jonathan Chang, Equity Research, Leerink Partners: pleasure to host the management team of Mersana. We have ...

I’m part of the Leerink Partners equity research team. Marty Huber, CEO, Mersana: It’s a Jonathan Chang, Equity Research, Leerink Partners: pleasure to host the management team of Mersana.

Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all ...

KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including ...

Not all rosy However, not everyone is convinced by the prospect of ADCs, including Roche’s current CEO, Severin Schwan ... last year shares in Mersana Therapeutics, a small biotech specialised ...

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage ...

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...